One study using the RBE human CCA cell line treated with SP600125, an inhibitor of JNK, demonstrated enhanced TGF-β-induced cell apoptosis in a SMAD4-dependent manner, suggesting that JNK inhibition may be an ideal therapeutic candidate for the treatment of human CCA [233]. Here, SMAD4 is linked to cholangiocarcinoma.